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In this study, we discovered that NSD2 speciﬁcally interacts with the DNA-binding domain of andro-
gen receptor (AR) via its HMG domain, and the nuclear translocation of both NSD2 and AR is
enhanced in the presence of ligand. Furthermore, we also demonstrated that the over expression
of NSD2, but not of NSD2 (DSET) HMT-activity defective mutant, enhanced the mRNA level of PSA
in a dose-dependent manner. A chromatin immunoprecipitation assay showed that NSD2 protein
is recruited to the enhancer region of the PSA gene by AR in an agonist-enhanced manner. Taken
together, these results uncover a potential role for NSD2 in AR-mediated transcription, implicating
NSD2 in prostate carcinogenesis.
Structured summary:
MINT-7103766: NSD2 (uniprotkb:O96028) physically interacts (MI:0914) with alpha AR (uni-
protkb:P10275) by anti tag coimmunoprecipitation (MI:0007)
MINT-7103748: NSD2 (uniprotkb:O96028) physically interacts (MI:0915) with alpha AR (uni-
protkb:P10275) by two hybrid (MI:0018)
MINT-7103800, MINT-7103819: alpha AR (uniprotkb:P10275) binds (MI:0407) to NSD2 (uni-
protkb:O96028) by pull down (MI:0096)
MINT-7103785: NSD2 (uniprotkb:O96028) colocalizes (MI:0403) with alpha AR (uniprotkb:P10275) by
ﬂuorescence microscopy (MI:0416)
MINT-7103733: P53 (uniprotkb:P04637) physically interacts (MI:0915) with alpha AR (uniprotkb:P10275)
by two hybrid (MI:0018)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Nuclear receptor-binding SET domain-protein 2 (NSD2) is a
member in a group of histone methyltransferases (HMT) (NSD1,
NSD2/WHSC1/MMSET, NSD3/WHSC1L1) with speciﬁcity for Lys
4 of histone H3 (H3-K4), Lys 27 of histone H3 (H3-K27), and Lyschemical Societies. Published by E
ing 2; AR, androgen receptor;
unoprecipitation
Biochemistry and Molecular
c Metabolic Disease Research,
ax: +82 2 312 5041.20 of histone H4 (H4-K20) [1–4]. In recent studies, it was deter-
mined that NSD2 acts as a transcriptional corepressor by increas-
ing either histone H3-K27 methylation or H4-K20 methylation
[3,4]. In addition, NSD2 is required for normal development [4].
However, over expression of NSD2 induces transformation [5].
For example, in multiple myeloma the IgH gene is often fused to
NSD2, causing over expression of most of the NSD2 protein. The
IgH-NSD2 fusion protein is highly expressed in the myeloid line-
age owing to the high activity of the IgH promoter, and it is
thought that the misregulated and over expressed NSD2 contrib-
utes to oncogenesis [6]. Taken together, these observations indi-
cate that the SET domain within the NSD2 protein may be
responsible for promoting carcinogenesis in cases of NSD2 over
expression.lsevier B.V. All rights reserved.
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tional regulation. We have determined that NSD2 speciﬁcally
interacts with the DNA-binding domain of androgen receptor
(AR) via its HMG domain, and enhances AR-mediated transcrip-
tional activation in the presence of ligand. We have also demon-
strated that NSD2 proteins are targeted to the promoter region of
the PSA gene with ligand-bound AR and subsequently increase his-
tone H3-K4 methylation. Together, these data provide important
evidence that NSD2 is involved in AR-mediated transcription,
implicating NSD2 in the promotion of prostate carcinogenesis.
2. Materials and methods
2.1. Cell culture and reagents
Human MCF-7 and A549 cells were maintained in Dulbecco’s
modiﬁed Eagle’s medium (DMEM, Hyclone) with 10% fetal bovine
serum (FBS, Hyclone) and 1% antibiotics (Invitrogen) at 37 C un-
der 5% CO2. LNCaP cells were maintained in RPMI1640 (Gibco/
BRL) supplemented with 10% FBS. For treatment with agonist,
LNCaP cells were seeded at a density of 60–70% conﬂuency for
transfection. Cells in six-well plates were supplemented with
fresh medium 2 h before transfection with 1.5 lg DNA, according
to the manufacturer’s protocol for Effectene Transfection (Qia-
gen). After a 48 h incubation, cells were transferred into phenol
red-free RPMI 1640 medium with 10% charcoal-stripped FCS
(CS-FCS) (Life Technologies) for at least 3 days, followed by
replacement of the media with fresh CS-FCS supplemented with
1 nM synthetic androgen R1881 (NEN/Life sciences Products).
For the luciferase reporter assays, cell lysates were prepared
according to the manufacturer’s instructions (Promega). Relative
luciferase activities were plotted using the activity of AR in the
presence of ligand, R1881. The results were obtained from at
least three sets of transfections and presented as mean values.
The full-length AR gene and AR domains were subcloned into a
GST-fusion expression plasmid (pGEX4T-2, Amersham Biosci-
ences). The open reading frames for the AR gene and NSD2 gene
were obtained by polymerase chain reaction and subcloned in-
frame into the eukaryotic expression vectors, pSG5-HA and
pSG5-Flag (Stratagene).
2.2. In vitro pull-down assays
Recombinant proteins of GST-fused AR were expressed in Esch-
erichia coli. Bacterial cells were lysed in 5 ml binding buffer
(20 mM Hepes/pH 7.5, 100 mM NaCl, 5 mM b-mercaptoethanol,
and 10% glycerol). Recombinant proteins were puriﬁed by glutathi-
one-resin (Pharmacia) afﬁnity chromatography, according to the
manufacturer’s instructions. The equal concentration of GST-fused
proteins were incubated with 35S-labeled, TNT-expressed NSD2 for
4 h and washed extensively with 20 mM Hepes/pH 7.5, 0.5 mM
EDTA, 20% glycerol, 100 mM NaCl. The bound proteins were eluted
in 2 SDS loading buffer (100 mM Tris–HCl/pH 6.8, 4% SDS, 20%
glycerol, 200 mM b-mercaptoethanol), separated on 10% SDS–poly-
acrylamide gels, and analyzed by autoradiography.
2.3. In vitro methylation assay
LNCaP cells were transfected with plasmids encoding Flag-
tagged full-length NSD2 and the SET domain of NSD2 (residues
1011–1203), and tagged proteins were puriﬁed by immunoprecip-
itation with anti-Flag M2 beads (Sigma). The In vitro methyltrans-
ferase reaction was carried out in 20 ll reaction mixtures
containing 4 lg of core histones (Upstate), SAM (methyl donor;
NEB), and immunoprecipitated proteins. Samples were then sepa-rated by 15% SDS–polyacrylamide gel electrophoresis, andWestern
blot analysis was performed using antibodies against modiﬁed his-
tones (Upstate).
2.4. RNA extraction, real-time PCR analysis, and chromatin
immunoprecipitation (ChIP) assays
RNA extraction, real-time PCR, and ChIP were performed, as de-
scribed [7]. The antibodies against AR, ERa, and GR were purchased
from Upstate Biotechnology. The RT-PCR analysis and quantiﬁca-
tion was performed with SYBR Green PCR Master Mix reagents
on an ABI Prism 7300 Sequence Detection System. The singularity
and speciﬁcity of ampliﬁcation were veriﬁed by Dissociation
Analysis Software. All samples were normalized to human GAPDH.
Primer sequences for ampliﬁcation of NKX3-1 RNA were (F 50-
CTGTCAGCCCCTGAACGG-30, R 50-AACCATATCTTCACTTGGGTCTCC-
30). Primer sequences for ampliﬁcation of the PSA RNA were (F
50-AGTCTGAGGAGGTGTTCTGGTG-30, R 50-GAGGTCGTGGCTGGAGT-
CATCA-30). Primers used for ChIP analysis were: PSA (ARE1): 50-
TTGCATAAATTAGGGGAGAACATACCA-30, 50-GAGGGACCCAGCTGC-
GA-TTCA-30. All reactions were performed in triplicate. Relative
expression levels and S.D.s were calculated using the comparative
method.
3. Results
3.1. The histone H3-K4 methyltransferase, NSD2, speciﬁcally interacts
with AR
Epigenetic enzymes are targeted to speciﬁc chromatin domains
through interactions with DNA-bound activator or repressor pro-
teins. For example, the histone acetyltransferases (HAT), histone
deacetylases (HDAC), and HMT activate or repress the transcription
of genes via associations with chromatin-bound nuclear hormone
receptors (NRs) [8]. NSD1 has been found to act as a bifunctional
transcriptional cofactor, playing a dual role in transcription.
NSD1 has an intrinsic methyltransferase activity with speciﬁcity
for Lys36 of histone H3 (H3-K36) and Lys20 of histone H4K20
(H4-K20) [9]. Interestingly, NSD1 interacts with AR via its nuclear
receptor-interacting domains (NIDs) [10]. Thus, we ﬁrst sought to
determine whether NSD2 also interacts with nuclear hormone
receptors (NRs), including AR, glucocorticoid receptor (GR), and
estrogen receptor (ER). Towards this end, Flag-tagged NSD2 was
transfected into LNCaP, MCF7 and A549 cells, immunoprecipitated,
and subjected to Western blot analysis with antibodies against AR,
ER, and GR. As shown in Fig. 1A, the Flag-tagged NSD2 speciﬁcally
interacted with endogenous AR in LNCaP cells, but did not interact
with either ER or GR. To validate the results of the immunoprecip-
itation assays, we used the yeast two-hybrid and b-galactosidase
assay to conﬁrm the interaction between NSD2 and AR. For this
experiment, a MATa S.c Y187 (pACT:AR) strain was mated to a
MATa S.c AH109 bait strain transformed either recombinant
pGBKT7 encoding NSD2, or as a control, with the unrelated bait
p53, or the empty pGBKT7. While each bait strain mated success-
fully with the prey strain to generate diploids, the strain harboring
the empty vector pGBKT7 alone failed to show any interaction with
AR (Fig. 1B). Conversely, strains expressing NSD2 showed a strong
interaction with AR, as assessed by the b-galactosidase assay. As a
positive control for speciﬁcity, we also conﬁrmed a strong interac-
tion between the pGBKT7-p53 and pGADT7-T clone (Fig. 1B). In a
control experiment, we asked whether the over expressed Flag-
NSD2 possessed intrinsic HMT activity. To do this, we examined
the patterns of histone methylation of core histone substrates. In
agreement with a recent study [4], the immunoprecipitated
NSD2 and NSD2-SET domain proteins speciﬁcally methylated his-
Fig. 1. The histone H3-speciﬁc methyltransferase, NSD2, speciﬁcally interacts with AR. (A) NSD2 interacts with endogeneous AR, but not other NRs. LNCaP, MCF-7, and A549
cells were transfected with 1 lg of Flag-tagged NSD2 expression plasmid. Cell lysates were immunoprecipitated and subsequently immunoblotted with the antibodies, as
indicated. (B) Yeast two-hybrid assay using ADE, HIS3, and LacZ reporter genes to measure the interaction of AR and NSD2. AH109 yeast strain harboring various plasmids,
including pGBKT7-AR (aa 507–645), pGBKT7 vector alone, or pGBKT7-p53 mated to the opposite Y187 yeast strain harboring pACT2-NSD2 (aa 1–877), pGADT7 vector alone,
or pGADT7-SV40 T antigen. Diploid colonies containing pGBKT7-AR and pGADT7-NSD2 were viable and turned blue on the high-strigency selection plate, indicating that the
two proteins interact. The speciﬁcity of the interaction was conﬁrmed by the absence of protein interaction in the negative control. The plates were incubated at 30 C for 3–
5 days. (C) NSD2 is a histone methyltransferase speciﬁc for histone H3-K4 and H3-K9. LNCaP cells were transfected with 1 lg of plasmid expressing either Flag-tagged NSD2
full-length (NSD2-F) or the SET domain of NSD2 (NSD2-SET). Cell lysates were immunoprecipitated and incubated in vitro with histone substrates and SAM. Western blot
analysis was performed with the indicated antibodies. CBB, Coomasie blue staining.
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methylated histone H3-K9, in vitro. Collectively, these results dem-
onstrate an association between AR and NSD2, a member of the
HMT family.
3.2. The N-terminal domain of NSD2 interacts with the DNA-binding
domain of AR
We next wished to elucidate the structure and function of NSD2
and AR with respect to their interaction domains. To conﬁrm the
association of NSD2 and AR in vivo, we performed immunostaining
analysis after transfection of Flag-tagged NSD2 in LNCaP cells. We
found that the nuclear translocation of both NSD2 and AR was en-
hanced in the presence of ligand (Fig. 2A). Indeed, we also observed
co-localization of both proteins throughout the nucleus in the ab-
sence of a ligand, although to a lesser extent than in the presence of
ligand, indicating that a signiﬁcant fraction of NSD2 co-localizes
with AR in the nucleus.
Since, unlike NSD1, NSD2 has no nuclear hormone receptor-
interaction domains (NIDs), we next mapped the interaction do-
mains of NSD2 and AR. For this experiment, the AR protein was di-
vided into three fragments, as shown in Fig. 2C, and their
interaction with NSD2 was tested in in vitro pull-down assays.
The results showed that the in vitro translated NSD2 (1–877) frag-
ment containing the N-terminal domain interacted with the DNA-
binding domain of GST-AR. Since secondary structure analysisfailed to identify the consensus sequences of either a nuclear hor-
mone receptor (NR) or a co-repressor nuclear receptor (CoRNR)
box in the N-terminal domain of NSD2, we next sought to more
precisely map the interaction of AR with NSD2 (1–877). To do this,
we constructed several new expression constructs derived from
NSD2 (1–877) (Fig. 2C, upper panel). When tested in in vitro
pull-down assays, the region including the HMG domain of NSD2
(NSD2N-2) interacted efﬁciently with the DNA-binding domain of
AR (Fig. 2C). Thus, the minimal interaction domain was mapped
to the region between NSD2 286–652. Taken together, we con-
cluded that NSD2 interacts with the DNA-binding domain of AR
via its HMG domain.
3.3. NSD2 enhanced ligand-bound AR-mediated transcriptional
activation
A recent study related to the development of multiple myeloma
demonstrated that NSD2 protein possesses methyltransferase
activity with speciﬁcity for histone H3-K4 and H4-K20, and re-
presses transcription by increasing H4-K20 methylation in gene
promoters [4]. Another study suggested that the MMSET short iso-
form, RE-IIBP, is a H3-K27 speciﬁc methyltransferase and tran-
scriptional repressor [2]. These studies commonly indicated that
the corepressor, NSD2, mediates transcriptional repression by
increasing the amount of repressive histone signals. In this study,
we characterized the histone H3-K4 methyltransferase activity of
Fig. 2. The HMG domain of NSD2 interacts with the DNA-binding domain of AR. (A) Ligand-bound AR and NSD2 co-localize in the nucleus. Both Flag-NSD2 and HA-AR
expression plasmids were transfected into LNCaP cells, ﬁxed, and then immunostained with indicated antibodies. (B) The N-terminal domain (residues 1–877) of NSD2
interacts with the DNA-binding domain of AR. A schematic diagram of the various deletion mutants of NSD2 for in vitro translation and AR fused to GST utilized in the
mapping studies (upper panel). In vitro translated, 35S-labeled NSD2 deletion mutants were incubated with GST-AR deletion mutants and bound in vitro translated NSD2
deletion mutants were subjected to SDS–PAGE followed by autoradiography (lower panel). (C) The region that includes the HMG domain of NSD2 (residues 286–652)
interacted efﬁciently with the DNA-binding domain of AR. A schematic diagram of the various deletion mutants of NSD2N utilized in the mapping studies (upper panel). In
vitro transcribed/translated 35S-labeled NSD2 (residues 1–877) deletion mutants were incubated with GST-AR (DBD) and the bound in vitro translated NSD2 proteins were
subjected to SDS–PAGE followed by autoradiography (lower panel).
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tion is a hallmark of transcriptional activation, we next tested
whether NSD2 enhances AR-mediated transcriptional activation.
Toward this end, LNCaP cells were ﬁrst transiently transfected with
androgen responsive element (ARE)-Luc-SV40 reporter DNA [11]
and Flag-NSD2 or a control DNA for 2 days. The collected cells were
then lysed and the relative activity of luciferase was measured. As
shown in Fig. 3A, transient transfection with increasing amounts of
NSD2 led to increased luciferase activity, enhancing the activity le-
vel to 2.5-fold of R1881-induced transcription. This result revealed
a crucial role for NSD2 in AR-mediated transcriptional activation.
To further evaluate the role of NSD2 in AR-mediated transcription,
we performed quantitative real-time PCR (qPCR) analysis for the
endogeneous AR-regulated genes, PSA and NKX3.1. For this pur-
pose, LNCaP cells were transfected with or without NSD2. Two
days later, the cells were treated with or without R1881 for 1 h
and processed for real-time PCR analysis. In agreement with tran-
sient transfection assay, the qPCR analysis (Fig. 3B) showed that
the over expression of NSD2 enhanced the mRNA level of PSA in
a dose-dependent manner. Under the same conditions, the expres-
sion of NKX3.1 was also enhanced by over expressed NSD2. As ex-
pected, no effect on actin gene expression was observed. In
contrast, we did not observe signiﬁcant changes in the activation
of AR-dependent transcription in an experiment in which the SET
domain (residues 1011–1203) of NSD2 was deleted (Fig. 3C). In
summary, NSD2, through its SET domain, cooperates with AR
in vivo and enhances the transcriptional activity of agonist-bound
AR.3.4. Both NSD2 and ligand-bound AR are recruited to the promoter
region of the PSA gene
To test whether NSD2 interacts with agonist-bound AR on chro-
matin, we ﬁrst determined whether NSD2 is recruited to the PSA
enhancer or promoter in LNCaP cells treated with or without ago-
nist R1881 using the ChIP assay. Consistent with results in a previ-
ous report [11], we found that the association of AR with the
enhancer peaked around 30 min and persisted at least 4 h after
addition of R1881 (data not shown). A representative example of
the ChIP results is displayed in Fig. 4 and shows that both AR
and NSD2 were targeted to the PSA distant enhancer in the pres-
ence of agonist R1881, but not in the control IgG. The histone
H3-K4 dimethylation was dramatically increased upon recruit-
ment of NSD2 to the PSA distant enhancer. However, there was
no effect on the levels of H3-K9 and H3-K27 methylation, suggest-
ing a selective modiﬁcation of the histone code by NSD2 during
transcriptional activation. These results substantiate that NSD2
proteins are targeted to the PSA gene along with AR in an ago-
nist-enhanced manner.
4. Discussion
Histone lysine methylation is a functionally complex process as,
depending on sequence-speciﬁc lysine methylation sites in his-
tones and on the methylation state of the e-amino group of the tar-
get lysine, it can either activate or repress transcription [12]. For
instance, H3-K27 mono-methylation and H3-K9 trimethylation oc-
Fig. 3. NSD2 enhances AR-mediated transcriptional activation in the presence of agonist. (A) NSD2 enhances ligand-dependent AR transcription. LNCaP cells were transfected
with PSA promoters (4115/4006), Luc, and either control plasmid or Flag-tagged NSD2. Cells were treated for 6 h with R1881 (1 nM) and ﬁreﬂy versus Renilla luciferase
activities were determined for triplicate samples. (B) NSD2 enhances the mRNA levels of AR-regulated genes, PSA and NKX3.1. LNCaP cells were transfected with control
plasmid or Flag-tagged NSD2, as indicated. After 2 days, the cells were treated with or without R1881 for 1 h and the levels of transcription from PSA and NKX3-1 were
analyzed by quantitative real-time PCR. The levels of transcription are shown as fold-induction, with the level of transcription in the absence of R1881 set to 1. The results are
shown as mean ± S.D. calculated from three independent experiments. A one-way ANOVA test was used to determine the effects of the over expression of NSD2. *P < 0.05 vs
control. (C) The HMTase activity of NSD2 is required for enhancing AR-mediated transcription. LNCaP cells were transfected with either Flag-tagged NSD2 plasmid or NSD2
(DSET), as indicated. After treatment with or without R1881 for 1 h, the levels of transcription from PSA was analyzed by quantitative real-time PCR.
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thylation and H3-K9 dimethylation are epigenetic imprints of inac-
tive X chromosomes [13]. Moreover, studies in yeast have shown
that trimethylation of H3-K4 by Set1p, together with H3-K36
methylation by Set2p, functionally regulates transcriptional elon-
gation [14,15]. The SET domain of Set1p closely resembles the
mixed-lineage leukemia (MLL) SET domain in humans, which also
possesses methyltransferase activity towards H3-K4 and leads to
transcriptional activation at Hox gene promoters [16]. The NSD1
protein belongs to same family as NSD2 and NSD3 and was initially
identiﬁed as an AR-interacting protein through two distinct nucle-
ar receptor-interaction domains. NSD2 is a novel SET protein that
exhibits characteristics of both corepressors and coactivators. Since
epigenetic modulating enzymes, such as HDACs, HATs, and
HMTase mainly participate in NR-mediated transcriptional regula-
tion via modiﬁcation of the histone code, we ﬁrst examined
whether, like NSD1, NSD2 physically interacts with AR. The results
of pull-down assays clearly demonstrated a speciﬁc interaction be-
tween AR and NSD2, in both in vitro and in vivo, and did not show
an interaction between NSD2 and other NRs.
It has been recently demonstrated that the HMT, NSD2, pos-
sesses speciﬁc enzyme activities against histone H3-K4 and H4-
K20, and NSD2-mediated repression has been associated with in-
creased H4-K20 methylation. On the other hand, a small isoformof NSD2, RE-IIBP (interleukin-5 [IL-5] response element II binding
protein), has been shown to exhibit histone H3-K27 methyltrans-
ferase activity, and also repress the transcription of the IL-5 gene
via association with HDAC 1/2 (histone deacetylase). Based on
these studies, the major function of NSD2 seems to be as a tran-
scriptional repressor via increasing either H3-K27 or H4-K20
methylation. Unlike these other studies, in this study immunopre-
cipitated NSD2 speciﬁcally methylated core histone H3-K4, but not
H3-K27 or H4-K20. Since histone K3-K4 methylation is a hallmark
for transcriptional activation, this result led us to examine whether
NSD2 increases AR-mediated transcription. Using a reporter assay,
we concluded that NSD2 enhances AR-mediated transcriptional
activation. Quantitative RT-PCR analysis further conﬁrmed a role
for NSD2 in AR-mediated transcriptional activation. Finally, a ChIP
assay demonstrated that NSD2 proteins can be targeted to the PSA
gene in an agonist-bound AR- dependent manner. In agreement
with this result, immunostaining showed an enhanced co-localiza-
tion pattern for NSD2 and AR in the nucleus in cells treated with AR
ligand. This is a somewhat unexpected result because the main
function of NSD2 was thought to be corepression. Some of HMTa-
ses act as both coactivators and corepressors [10,17]. NSD1 has
been shown to methylate two histone sites, H3-K36 and H4-K20,
and also repress or activate transcription depending on the pres-
ence of ligand. Similar to NSD1, NSD2 may be a highly versatile
Fig. 4. NSD2 proteins are targeted to the PSA gene with AR in an agonist-enhanced manner. The relative positions of previously identiﬁed AREs in the promoter and enhancer
are illustrated in the top panel. LNCaP cells were transfected with Flag-tagged NSD2, and then treated with R1881 (1 nM) for 1 h. The recruitment of NSD2, AR, and the
modiﬁcation of histone H3 in the promoter of PSA was then determined by ChIP assays using antibodies, as indicated. The results were analyzed by real-time PCR and are
shown as the percentage of input. The results are shown as means ± S.D. calculated from three independent experiments.
H.-B. Kang et al. / FEBS Letters 583 (2009) 1880–1886 1885NR intermediary factor controlling transcription either negatively
or positively, depending on both the promoter context of the target
genes and the cell context with respect to other factors interacting
with NSD2. Further molecular and biochemical studies will be re-
quired to unravel the functions of NSD2.
Acknowledgements
This work was supported by the Korea Science and Engineering
Foundation (KOSEF) grant funded by the Korea government
(MOST) (R13-2002-054-04002-0 and M1075502001-07N5502-
00110); by a grant (Code #20070301034007) from BioGreen 21
program, Rural Development Administration, Republic of Korea;
by the Korea Research Foundation Grant funded by the Korean
Government (MOEHRD, Basic Research Promotion Fund) (KRF-
2008-314-E00029) (to H.G. Yoon).
References
[1] Douglas, J., Coleman, K., Tatton-Brown, K., Hughes, H.E., Temple, I.K., Cole, T.R.
and Rahman, N. (2005) Evaluation of NSD2 and NSD3 in overgrowth
syndromes. Eur. J. Hum. Genet. 13, 150–153.
[2] Kim, J.Y., Kee, H.J., Choe, N.W., Kim, S.M., Eom, G.H., Baek, H.J., Kook, H., Kook,
H. and Seo, S.B. (2008) Multiple-myeloma-related WHSC1/MMSET isoform RE-
IIBP is a histone methyltransferase with transcriptional repression activity.
Mol. Cell. Biol. 28, 2023–2034.[3] Lauring, J., Abukhdeir, A.M., Konishi, H., Garay, J.P., Gustin, J.P., Wang, Q.,
Arceci, R.J., Matsui, W. and Park, B.H. (2008) The multiple myeloma associated
MMSET gene contributes to cellular adhesion, clonogenic growth, and
tumorigenicity. Blood 111, 856–864.
[4] Marango, J., Shimoyama, M., Nishio, H., Meyer, J.A., Min, D.J., Sirulnik, A.,
Martinez-Martinez, Y., Chesi, M., Bergsagel, P.L., Zhou, M.M., Waxman, S.,
Leibovitch, B.A., Walsh, M.J. and Licht, J.D. (2008) The MMSET protein is a
histone methyltransferase with characteristics of a transcriptional
corepressor. Blood 111, 3145–3154.
[5] Brito, J.L., Walker, B., Jenner, M., Dickens, N.J., Brown, N.J., Ross, F.M.,
Avramidou, A., Irving, J.A., Gonzalez, D., Davies, F.E. and Morgan, G.J. (2009)
MMSET deregulation affects cell cycle progression and adhesion regulons in
t(4;14) myeloma plasma cells. Haematologica 94, 78–86.
[6] Intini, D., Fabris, S., Storlazzi, T., Otsuki, T., Ciceri, G., Verdelli, D., Lombardi, L.,
Rocchi, M. and Neri, A. (2004) Identiﬁcation of a novel IGH-MMSET fusion
transcript in a human myeloma cell line with the t(4;14)(p16.3;q32)
chromosomal translocation. Br. J. Haematol. 126, 437–439.
[7] Yoon, H.G., Choi, Y., Cole, P.A. and Wong, J. (2005) Reading and function of a
histone code involved in targeting corepressor complexes for repression. Mol.
Cell. Biol. 25, 324–335.
[8] Margueron, R., Trojer, P. and Reinberg, D. (2005) The key to development:
interpreting the histone code? Curr. Opin. Genet. Dev. 15, 163–176.
[9] Rayasam, G.V., Wendling, O., Angrand, P.O., Mark, M., Niederreither, K., Song,
L., Lerouge, T., Hager, G.L., Chambon, P. and Losson, R. (2003) NSD1 is essential
for early post-implantation development and has a catalytically active SET
domain. EMBO J. 22, 3153–3163.
[10] Huang, N., vom Baur, E., Garnier, J.M., Lerouge, T., Vonesch, J.L., Lutz, Y.,
Chambon, P. and Losson, R. (1998) Two distinct nuclear receptor interaction
domains in NSD1, a novel SET protein that exhibits characteristics of both
corepressors and coactivators. EMBO J. 17, 3398–3412.
[11] Yoon, H.G. andWong, J. (2006) The corepressors silencing mediator of retinoid
and thyroid hormone receptor and nuclear receptor corepressor are involved
1886 H.-B. Kang et al. / FEBS Letters 583 (2009) 1880–1886in agonist- and antagonist-regulated transcription by androgen receptor. Mol.
Endocrinol. 20, 1048–1060.
[12] Martin, C. and Zhang, Y. (2005) The diverse functions of histone lysine
methylation. Nat. Rev. Mol. Cell. Biol. 6, 838–849.
[13] Kustatscher, G. and Ladurner, A.G. (2007) Modular paths to ‘decoding’ and
‘wiping’ histone lysine methylation. Curr. Opin. Chem. Biol. 11, 628–635.
[14] Krogan, N.J., Kim, M., Tong, A., Golshani, A., Cagney, G., Canadien, V., Richards,
D.P., Beattie, B.K., Emili, A., Boone, C., Shilatifard, A., Buratowski, S. and
Greenblatt, J. (2003) Methylation of histone H3 by Set2 in Saccharomyces
cerevisiae is linked to transcriptional elongation by RNA polymerase II. Mol.
Cell. Biol. 23, 4207–4218.[15] Morillon, A., Karabetsou, N., Nair, A. and Mellor, J. (2005) Dynamic lysine
methylation on histone H3 deﬁnes the regulatory phase of gene transcription.
Mol. Cell 18, 723–734.
[16] Guenther, M.G., Jenner, R.G., Chevalier, B., Nakamura, T., Croce, C.M., Canaani,
E. and Young, R.A. (2005) Global and Hox-speciﬁc roles for the MLL1
methyltransferase. Proc. Natl. Acad. Sci. USA 102, 8603–8608.
[17] Fauquier, L., Duboe, C., Jore, C., Trouche, D. and Vandel, L. (2008) Dual role of
the arginine methyltransferase CARM1 in the regulation of c-Fos target genes.
FASEB J. 22, 3337–3347.
